Clinical Trial Update: A Phase I/II, Multi-Center, Open-Label, Dose-Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients With Advanced Pancreatic Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II open-label dose-escalation study of PHY906 plus capecitabine in advanced pancreatic cancer evaluated safety and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• PHY906

Snippet

Sponsor: Yale University | Conditions: Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-03-27